Holen Sie sich die Stockscreener-App
2.42
26.44%
-0.87
Schlusskurs vom Vortag:
$3.29
Offen:
$3.88
24-Stunden-Volumen:
4.32M
Relative Volume:
10.49
Marktkapitalisierung:
$84.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.08M
KGV:
-3.3151
EPS:
-0.73
Netto-Cashflow:
$-33.68M
1W Leistung:
+76.64%
1M Leistung:
+87.60%
6M Leistung:
+132.69%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.85
$3.9035
1-Wochen-Bereich:
$1.38
$3.9035
52-Wochen-Spanne:
$0.726
$3.9035
Galectin Therapeutics Inc Stock (GALT) Company Profile
Firmenname
Galectin Therapeutics Inc
Sektor
Branche
Telefon
678-620-3186
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Vergleichen Sie GALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.42 | 84.81M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-13 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Herabstufung | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Herabstufung | ROTH Capital | Buy → Sell |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-09-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-08-01 | Herabstufung | Aegis Capital | Buy → Hold |
| 2014-07-30 | Bestätigt | MLV & Co | Buy |
| 2014-07-29 | Bestätigt | MLV & Co | Buy |
| 2014-04-02 | Bestätigt | MLV & Co | Buy |
| 2014-02-10 | Bestätigt | Aegis Capital | Buy |
| 2014-01-09 | Bestätigt | Aegis Capital | Buy |
| 2013-12-03 | Eingeleitet | MLV & Co | Buy |
| 2013-08-19 | Bestätigt | Aegis Capital | Buy |
Alle ansehen
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
Galectin Therapeutics (NASDAQ:GALT) Now Covered by Analysts at HC Wainwright - Defense World
Galectin Therapeutics stock rating initiated at buy by H.C. Wainwright - Investing.com Nigeria
Analyst Forecast For Galectin Therapeutics Inc (NASDAQ: GALT) - Stocksregister
Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainw - GuruFocus
HC Wainwright Initiates Coverage on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
HC Wainwright & Co. Initiates Coverage with Buy Rating on GALT | - GuruFocus
Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainwright | GALT Stock News - GuruFocus
Transcript : Galectin Therapeutics Inc.Special Call - MarketScreener
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belap - GuruFocus
Galectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension Treatment - Nasdaq
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension - Yahoo Finance
MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight - The Globe and Mail
Northern Trust Corp Purchases 9,994 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Inc (NASDAQ: GALT) Stock: Investors Need To Know This - Stocksregister
Portal Hypertension Market Growth Projections 2023-2032: - openPR.com
MASH Market Report 2034: Statistics, Revenue, Patient Pool, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Galectin Therapeutics (GALT) to Release Earnings on Thursday - MarketBeat
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | G - GuruFocus
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | GALT Stock News - GuruFocus
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update - The Manila Times
Galectin Therapeutics Reports Q1 2025 Financial Results and Business Update - TradingView
GALECTIN THERAPEUTICS INC SEC 10-Q Report - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Barclays PLC Purchases 26,047 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Wednesday - Defense World
Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight - PR Newswire UK
Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com Canada
Galectin Therapeutics Presents NAVIGATE Study Data Of Belapectin At EASL 2025 Congress - Nasdaq
Galectin Therapeutics (GALT) Reveals Promising NAVIGATE Study Re - GuruFocus
Belapectin shows promise in MASH cirrhosis trial - Investing.com Australia
Galectin Therapeutics Updates Corporate Presentation on Belapectin - TipRanks
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - The Manila Times
Galectin Therapeutics Inc. Reports Positive NAVIGATE Trial Results for Belapectin in MASH Cirrhosis Treatment - Nasdaq
Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Position Boosted by JPMorgan Chase & Co. - Defense World
Renaissance Technologies LLC Decreases Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - The AM Reporter
9 Short Squeeze Stocks That Could Take Off - US News Money
Geode Capital Management LLC Has $1.12 Million Stake in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
LPL Financial LLC Has $179,000 Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
RBC Capital Keeps Their Buy Rating on Brookfield Infrastructure (BIP) - The Globe and Mail
Will Alphabet Stock Keep Rising After Crushing Q1 Earnings Expectations? - The Globe and Mail
CEO.CA's Inside the Boardroom: Yukon Metals CEO Breaks Down Upcoming Drilling Plans for Star River Gold-Silver and AZ Copper Targets - The Globe and Mail
MASH Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Patient Pool, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Commonwealth Equity Services LLC Reduces Stock Position in Galectin Therapeutics Inc. (NASDAQ:GALT) - MarketBeat
Game-Changing MASH Cirrhosis Treatment Results: New Clinical Data Shows Promise in Portal Hypertension - Stock Titan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Commonwealth Equity Services LLC - Defense World
HC Wainwright Analysts Boost Earnings Estimates for GALT - MarketBeat
FY2029 Earnings Forecast for GALT Issued By HC Wainwright - MarketBeat
Psoriasis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Galectin Therapeutics (NASDAQ:GALT) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Galectin Therapeutics Inc-Aktie (GALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shlevin Harold H. | Director |
Dec 30 '24 |
Buy |
1.16 |
6,500 |
7,540 |
15,206 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
40,000 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Sale |
0.88 |
13,654 |
12,044 |
26,346 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Option Exercise |
0.00 |
56,000 |
0 |
953,012 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Sale |
0.89 |
56,000 |
49,610 |
897,012 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
47,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Sale |
0.89 |
40,000 |
35,492 |
7,614 |
| Zordani Richard A. Jr. | Director |
Dec 24 '24 |
Buy |
0.82 |
10,000 |
8,164 |
42,083 |
| ELDRED KARY | Director |
Dec 24 '24 |
Buy |
0.82 |
13,469 |
11,045 |
63,682 |
| FREEMAN KEVIN D | Director |
Dec 24 '24 |
Buy |
0.81 |
10,000 |
8,134 |
44,769 |
1.86%
1.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):